Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0MBYJG
ADC Name	CDH6-SPDB-DM4
Synonyms	CDH6 SPDB DM4 Click to Show/Hide
Drug Status	Investigative
Indication	In total 5 Indication(s) Epithelial ovarian cancer [ICD11:2B5D] Investigative Fallopian tube cancer [ICD11:2C74] Investigative Ovarian cancer [ICD11:2C73] Investigative Peritoneal cancer [ICD11:2C51] Investigative Renal cell carcinoma [ICD11:2C90] Investigative
Structure
	3D MOL	2D MOL
Antibody Name	Human Anti-CDH6 mAb		Antibody Info
Antigen Name	Cadherin-6 (CDH6)		Antigen Info
Payload Name	Mertansine DM4		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)		Linker Info
Conjugate Type	Lysine residue on the antibody is conjugated via an amide bond to the linker-payload moiety.
Combination Type	Ravtansine

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 3 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 45	%	Ovarian cancer cells	Ovarian cancer
Tumor Growth Inhibition value (TGI)	≈ 50	%	Ovarian cancer cells	Ovarian cancer
Tumor Growth Inhibition value (TGI)	≈ 100	%	OVCAR-3 cells	Ovarian serous adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 45.00% (Day 45)	High CDH6 expression (CDH6+++)
Method Description	CDH6-SPDB-DM4 induces efficient tumor cell killing in cell PDX models with CDH6 expression.
In Vivo Model	Ovarian cancer CDX model
In Vitro Model	Ovarian cancer	Ovarian cancer cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 50.00% (Day 45)	High CDH6 expression (CDH6+++)
Method Description	CDH6-SPDB-DM4 induces efficient tumor cell killing in cell PDX models with CDH6 expression.
In Vivo Model	Ovarian cancer CDX model
In Vitro Model	Ovarian cancer	Ovarian cancer cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 45)	High CDH6 expression (CDH6+++)
Method Description	CDH6-SPDB-DM4 induces efficient tumor cell killing in cell PDX models with CDH6 expression.
In Vivo Model	Ovarian cancer CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

References

Ref 1	Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers. Cancer Discov. 2017 Sep;7(9):1030-1045.